JHP Pharmaceuticals acquired by Warburg Pincus for $195 million

US specialty drugmaker JHP Pharmaceuticals, which acquires, develops, manufactures and sells sterile injectable products, announced on December 31 that it has been acquired by an affiliate of private equity firm Warburg Pincus, from JHP Holdings, an entity majority-owned by Morgan Stanley Principal Investments, for $195 million on a debt-free, cash-free basis. JHP's current management team will continue to hold an interest in the company. Additional terms of the transaction were not disclosed.

Since its founding in 2007, JHP has developed into a leading specialty pharmaceutical company focused on the $30 billion US sterile injectable drug market. JHP's established market presence, high-quality sterile manufacturing facility, and experienced management team, coupled with growth capital and support from Warburg Pincus, will enable the company to pursue unique partnership and acquisition opportunities in both the branded and generic segments of the sterile injectable market.

JHP has strong branded and generic injectables portfolio